Vistagen advances Phase 3 SAD trials with 2025 data readout target
Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...
Verywell Health18 小时
Why You Feel Anxious the Day After Drinking, Written By a Neurologist
Hangxiety describes feeling anxious after a session of drinking alcohol. Learn why it happens, what to do, and how to prevent ...
Rolling Out20 小时
Unfamiliar signs of anxiety that change lives
Mental health professionals reveal the hidden signs of anxiety disorders affecting millions of Americans, from mysterious ...